(DRIO) DarioHealth - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23725P2092
DRIO: Digital, Therapeutics, Devices, Coaching
DarioHealth Corp (NASDAQ:DRIO) is a digital health company operating in the United States, Canada, the European Union, Australia, and New Zealand. The company specializes in delivering personalized digital therapeutics and dynamic interventions through its platform, leveraging data analytics and one-on-one coaching. Its solutions address chronic conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The product portfolio includes Dario Evolve, a metabolic health solution for diabetes, pre-diabetes, hypertension, and weight management; Dario Move, targeting common musculoskeletal conditions; Dario Elevate, a behavioral health solution optimizing evidence-based care access; and Dario One, a comprehensive suite for chronic condition management. Additionally, the company offers native devices, including glucose meters, blood pressure cuffs, digital scales, and biofeedback sensors, alongside live coaching services. DarioHealth Corp, formerly known as LabStyle Innovations Corp, was incorporated in 2011 and is headquartered in New York, New York.
Based on
Additional Sources for DRIO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DRIO Stock Overview
Market Cap in USD | 27m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2014-10-06 |
DRIO Stock Ratings
Growth 5y | -89.9% |
Fundamental | -40.4% |
Dividend | 0.0% |
Rel. Strength Industry | -59.9 |
Analysts | 5/5 |
Fair Price Momentum | 0.39 USD |
Fair Price DCF | - |
DRIO Dividends
No Dividends PaidDRIO Growth Ratios
Growth Correlation 3m | -55.6% |
Growth Correlation 12m | -90.3% |
Growth Correlation 5y | -89.7% |
CAGR 5y | -32.40% |
CAGR/Max DD 5y | -0.33 |
Sharpe Ratio 12m | -0.03 |
Alpha | -69.88 |
Beta | 1.41 |
Volatility | 90.12% |
Current Volume | 79.3k |
Average Volume 20d | 181.6k |
As of March 14, 2025, the stock is trading at USD 0.65 with a total of 79,328 shares traded.
Over the past week, the price has changed by -10.69%, over one month by -0.23%, over three months by -11.40% and over the past year by -59.98%.
Probably not. Based on ValueRay Fundamental Analyses, DarioHealth (NASDAQ:DRIO) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -40.43 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DRIO as of March 2025 is 0.39. This means that DRIO is currently overvalued and has a potential downside of -40%.
DarioHealth has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy DRIO.
- Strong Buy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DRIO DarioHealth will be worth about 0.4 in March 2026. The stock is currently trading at 0.65. This means that the stock has a potential downside of -33.85%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.2 | 387.7% |
Analysts Target Price | 3.5 | 438.5% |
ValueRay Target Price | 0.4 | -33.8% |